BIOMAT Database Logo BIOMAT Database Logo

[Synthesis and pharmacologic action of chiral fomocaine ((4-[2-methyl-3-(morpholin-4-yl)propyl)benzyl)-phenyl-ether and (4-(1-methyl-3-(morpholin-4-yl)propyl]benzyl)-phenyl-ether). 13. Synthesis of new compounds with local anesthetic action]. 2001

H Oelschläger, and P Glassl, and A Seeling, and J Wange, and M Listing, and B Jung
Institut für Pharmazie, Friedrich-Schiller-Universität, Jena, Germany.

The syntheses of two chiral fomocaines namely rac ((4-[2-methyl-3-(morpholin-4-yl)propyl]-benzyl)-phenyl-ether (O/G 3) and rac (4-[1-methyl-3-(morpholin-4-yl)propyl]benzyl)-phenyl-ether) (O/G 5) are reported. These compounds are part of a new research program concerning the relation between chirality and local anaesthetic activity in the group of fomocaines. The yield over five steps is in the range of 9% (O/G 3) up to 19.2% (O/G 5). The racemates were resoluted via the diastereomeric salts formed with (+)- or (-)-camphersulfonic acid. The chromatographic resolution in analytical scale is successful using a Daicel OD-column. The enantiomers are stable. The surface anaesthesia of the racemates as well as of the enantiomeres is weaker in comparison with fomocaine. The rate of tissue irritation is higher. The LD50 (mouse i.v.) is in the range between 290-390 mg/kg, while fomocaine shows a LD50 value of 175 mg/kg.

UI MeSH Term Description Entries
D007202 Indicators and Reagents Substances used for the detection, identification, analysis, etc. of chemical, biological, or pathologic processes or conditions. Indicators are substances that change in physical appearance, e.g., color, at or approaching the endpoint of a chemical titration, e.g., on the passage between acidity and alkalinity. Reagents are substances used for the detection or determination of another substance by chemical or microscopical means, especially analysis. Types of reagents are precipitants, solvents, oxidizers, reducers, fluxes, and colorimetric reagents. (From Grant & Hackh's Chemical Dictionary, 5th ed, p301, p499) Indicator,Reagent,Reagents,Indicators,Reagents and Indicators
D007928 Lethal Dose 50 The dose amount of poisonous or toxic substance or dose of ionizing radiation required to kill 50% of the tested population. LD50,Dose 50, Lethal
D008862 Microsomes, Liver Closed vesicles of fragmented endoplasmic reticulum created when liver cells or tissue are disrupted by homogenization. They may be smooth or rough. Liver Microsomes,Liver Microsome,Microsome, Liver
D009025 Morpholines Tetrahydro-1,4-Oxazines,Tetrahydro 1,4 Oxazines
D010647 Phenyl Ethers Ethers that are linked to a benzene ring structure. Diphenyl Oxide,Diphenyl Oxides,Diphenyl Ethers,Ethers, Diphenyl,Ethers, Phenyl,Oxide, Diphenyl,Oxides, Diphenyl
D002851 Chromatography, High Pressure Liquid Liquid chromatographic techniques which feature high inlet pressures, high sensitivity, and high speed. Chromatography, High Performance Liquid,Chromatography, High Speed Liquid,Chromatography, Liquid, High Pressure,HPLC,High Performance Liquid Chromatography,High-Performance Liquid Chromatography,UPLC,Ultra Performance Liquid Chromatography,Chromatography, High-Performance Liquid,High-Performance Liquid Chromatographies,Liquid Chromatography, High-Performance
D002855 Chromatography, Thin Layer Chromatography on thin layers of adsorbents rather than in columns. The adsorbent can be alumina, silica gel, silicates, charcoals, or cellulose. (McGraw-Hill Dictionary of Scientific and Technical Terms, 4th ed) Chromatography, Thin-Layer,Thin Layer Chromatography,Chromatographies, Thin Layer,Chromatographies, Thin-Layer,Thin Layer Chromatographies,Thin-Layer Chromatographies,Thin-Layer Chromatography
D004987 Ethers Organic compounds having two alkyl or aryl groups bonded to an oxygen atom, as in the formula R1–O–R2.
D000779 Anesthetics, Local Drugs that block nerve conduction when applied locally to nerve tissue in appropriate concentrations. They act on any part of the nervous system and on every type of nerve fiber. In contact with a nerve trunk, these anesthetics can cause both sensory and motor paralysis in the innervated area. Their action is completely reversible. (From Gilman AG, et. al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 8th ed) Nearly all local anesthetics act by reducing the tendency of voltage-dependent sodium channels to activate. Anesthetics, Conduction-Blocking,Conduction-Blocking Anesthetics,Local Anesthetic,Anesthetics, Topical,Anesthetic, Local,Anesthetics, Conduction Blocking,Conduction Blocking Anesthetics,Local Anesthetics,Topical Anesthetics
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia

Related Publications

H Oelschläger, and P Glassl, and A Seeling, and J Wange, and M Listing, and B Jung
[Synthesis of new compounds with local anesthetic activity. 11. Synthesis and action of 4-(3-bibenzyl-4-yl-propyl)-morpholine, a bioisosteric fomocaine].
February 1988, Archiv der Pharmazie,
H Oelschläger, and P Glassl, and A Seeling, and J Wange, and M Listing, and B Jung
Synthesis of fluorinated 1-(3-morpholin-4-yl-phenyl)-ethylamines.
May 2003, Bioorganic & medicinal chemistry letters,
H Oelschläger, and P Glassl, and A Seeling, and J Wange, and M Listing, and B Jung
(E)-2-[2-(4-Chloro-benzyl-idene)hydrazin-yl]-4-[3-(morpholin-4-ium-4-yl)propyl-amino]-quinazolin-1-ium bis-(perchlorate).
June 2012, Acta crystallographica. Section E, Structure reports online,
H Oelschläger, and P Glassl, and A Seeling, and J Wange, and M Listing, and B Jung
[Synthesis of recent compounds with local anesthetic action. 10. Synthesis of fomocaine].
February 1986, Archiv der Pharmazie,
H Oelschläger, and P Glassl, and A Seeling, and J Wange, and M Listing, and B Jung
Methyl 2-benzyl-5-[1-(4-methoxy-phen-yl)-4-oxo-3-phenyl-azetidin-2-yl]-4-nitro-3-phenyl-pyrrolidine-2-carboxyl-ate.
September 2008, Acta crystallographica. Section E, Structure reports online,
H Oelschläger, and P Glassl, and A Seeling, and J Wange, and M Listing, and B Jung
Crystal structure of 3-(morpholin-4-yl)-1-phenyl-3-(pyridin-2-yl)propan-1-one.
January 2015, Acta crystallographica. Section E, Crystallographic communications,
H Oelschläger, and P Glassl, and A Seeling, and J Wange, and M Listing, and B Jung
3-Cyclo-propyl-1-(4-methyl-phenyl-sulfon-yl)piperidine-3,5-diol.
January 2012, Acta crystallographica. Section E, Structure reports online,
H Oelschläger, and P Glassl, and A Seeling, and J Wange, and M Listing, and B Jung
2-{2-[4-(4-Fluoro-phen-yl)piperazin-1-yl]-2-oxoeth-yl}-6-(morpholin-4-yl)-4-phenyl-pyridazin-3(2H)-one.
February 2011, Acta crystallographica. Section E, Structure reports online,
H Oelschläger, and P Glassl, and A Seeling, and J Wange, and M Listing, and B Jung
(Z)-1-(3-Mesityl-3-methyl-cyclo-but-yl)-2-(morpholin-4-yl)ethanone oxime.
April 2011, Acta crystallographica. Section E, Structure reports online,
H Oelschläger, and P Glassl, and A Seeling, and J Wange, and M Listing, and B Jung
Synthesis and pharmacological study of 1-acetyl/propyl-3-aryl-5-(5-chloro-3-methyl-1-phenyl-1H-pyrazol-4-yl)-2-pyrazoline.
October 2010, European journal of medicinal chemistry,
Copied contents to your clipboard!